title: Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Adriana E
authors.initials: AE
authors.lastname: Tron
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.|b N-of-One, Inc , Lexington , MA , USA.
authors.forename: Erika K
authors.initials: EK
authors.lastname: Keeton
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Minwei
authors.initials: M
authors.lastname: Ye
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.|c Drug Discovery Program, Ontario Institute for Cancer Research , Toronto , Canada.
authors.forename: Matias
authors.initials: M
authors.lastname: Casas-Selves
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Huawei
authors.initials: H
authors.lastname: Chen
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Keith S
authors.initials: KS
authors.lastname: Dillman
authors.affiliation: d Department of Haematology , University College London Cancer Institute , London , UK.
authors.forename: Rosemary E
authors.initials: RE
authors.lastname: Gale
authors.affiliation: d Department of Haematology , University College London Cancer Institute , London , UK.
authors.forename: Chloe
authors.initials: C
authors.lastname: Stengel
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Zinda
authors.affiliation: d Department of Haematology , University College London Cancer Institute , London , UK.
authors.forename: David C
authors.initials: DC
authors.lastname: Linch
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.
authors.forename: Zhongwu
authors.initials: Z
authors.lastname: Lai
authors.affiliation: d Department of Haematology , University College London Cancer Institute , London , UK.
authors.forename: Asim
authors.initials: A
authors.lastname: Khwaja
authors.affiliation: a Oncology iMed, AstraZeneca , Waltham , MA , USA.|e Oncology Drug Discover Unit, Takeda Pharmaceuticals International Co , Cambridge , MA , USA.
authors.forename: Dennis
authors.initials: D
authors.lastname: Huszar
mesh_terms: D001713:Biphenyl Compounds / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D000067780:ELAV-Like Protein 1 / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D053634:TYK2 Kinase / Q000235:genetics*; D053778:Thiazolidines / Q000627:therapeutic use*
chemical_list: C587575:AZD1208; D001713:Biphenyl Compounds; D000067780:ELAV-Like Protein 1; C098770:ELAVL1 protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D053778:Thiazolidines; D053634:TYK2 Kinase; C070139:TYK2 protein, human